brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Αντινεοπλασματικοί παράγοντες - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
tevimbra
novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Αντινεοπλασματικοί παράγοντες - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.
azacitidine celgene
celgene europe bv - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
refludan
celgene europe ltd. - λεπιρουδίνη - thromboembolism; thrombocytopenia - Αντιθρομβωτικοί παράγοντες - Αντιπηκτική αγωγή σε ενήλικες ασθενείς με ηπαρίνη θρομβοκυτοπενία τύπου ΙΙ και Θρομβοεμβολική νόσος ανάθεση παρεντερική ΑΝΤΙΘΡΟΜΒΩΤΙΚΗ. Η διάγνωση πρέπει να επιβεβαιώνεται από την ηπαρίνη-προκληθείσα αιμοπεταλίων ενεργοποίησης δοκιμή ή ισοδύναμο δοκιμή.
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - Η θαλιδομίδη - Πολλαπλό μυέλωμα - Ανοσοκατασταλτικά - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
refludan 50mg/vial pd.i.s.inf
celgene europe ltd, u.k. - lepirudin - ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ - 50mg/vial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
refludan 20mg/vial pd.i.s.inf
celgene europe ltd, u.k. - lepirudin - ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ - 20mg/vial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
thalidomide celgene 50mg/cap caps
celgene europe ltd, u.k. - thalidomide - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 50mg/cap - ΟΡΦΑΝΟ ΦΑΡΜΑΚΟ
istodax
celgene europe ltd. - romεμπεψίνη - Λέμφωμα, μη-hodgkin - Αντινεοπλασματικοί παράγοντες - θεραπεία των περιφερικών Τ-κυττάρων λέμφωμα (ptcl),.
betaisodona skin cleanser 4% w/v cutaneous solution
mundipharma pharmaceuticals ltd (0000003104) 13 othellos str, nicosia, 1685, 23661 - povidone-iodine - cutaneous solution - 4% w/v - povidone-iodine (0025655418) 4% w/v - povidone-iodine